PROCEPT BioRobotics Corporation - Common Stock (PRCT)

Spruce Point Capital warns of Procept BioRobotics' overstated market potential and growth claims, citing niche product limitations and valuation risks.

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.

Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%).

Royal Caribbean earns its spot on the Big Cap 20 with a best-possible 99 Composite Rating, putting it in the top 1% of all stocks.

PROCEPT BioRobotics stock gains as Q3 earnings beat estimates with revenue up 66% YoY, driven by strong system sales and consumable revenue growth.

The company sells systems that perform aquablation to treat enlarged prostates.

Jim Cramer discusses PROCEPT BioRobotics, Zoetis, Target and Consolidated Edison. "

Discover which robotics stocks to sell in August and why, ensuring you avoid potential market downturns and secure your investments.